Phase IV White Papers & Case Studies

  1. Late Stage Clinical Research Services Brochure 9/29/2016

    As a result of our holistic approach to Late Stage clinical programs and with our expertise in Product Life Cycle Management, INC Research/inVentiv Health is strategically positioned to collect real world, differentiating product evidence that can prepare our clients to more successfully go to market.

  2. Commercialize Oncology & Hematology Services Brochure 9/29/2016

    At INC Research/inVentiv Health, we are reinventing the way our oncology clients commercialize products to optimize performance, reduce risk, and expedite the delivery of healthcare innovation to patients worldwide. In the last five years, we have conducted over 250 full-service oncology programs in more than 65 countries.

  3. Commercial Regulatory Approval And Market Adoption Expertise Brochure 9/29/2016

    We’ve invested in a strategic mix of proprietary services and infrastructure that offers each client customized solutions through a singular team to thrive in the new market reality.

  4. InVentiv Health Late Stage Research Datasheet 3/4/2016

    In today’s competitive landscape, getting a drug on the market is no longer about meeting clinical trial requirements, receiving regulatory approval and launching the drug. Drug developers need to generate evidence that shows whether a drug works in the real world and the benefit and value it provides to the healthcare system and patient.

  5. Quality Assurance: Investigation Trials & Postmarketed Projects Phase I-IV 6/10/2014

    The function of Chiltern’s independent QA auditing group is to assess, for investigational trials or postmarketed projects (Phases I-IV), the state of compliance with ICH-GCP and/or applicable regulatory requirements, Standard Operating Procedures (SOPs), the study protocol and/or project plans.

  6. Phase IV Clinical Trials Brochure 5/29/2013

    INC Research/inVentiv Health Late Stage leaders help world–class companies bridge the gap from development to commercialization.

  7. Switching EDC Platforms To Rescue In-Flight Clinical Trials 5/7/2013

    The decision to switch an EDC platform for in-flight trials is not easy and is fraught with risks. A majority of companies continue to plough forward with higher costs and operational pains due to a failing EDC platform. Read this white paper and learn how Acceliant's low-risk EDC migration can deliver legacy EDC retirement, lower operating costs, and peace of mind for all teams working towards the success of a clinical trial. By Ven Thangaraj, CTO, Acceliant

  8. Brochure: Norwich Clinical Services 2/1/2013

    Norwich Clinical Services is a contract research organization that provides Bioanalytical Services, Pharmacovigilance and Clinical Research Programs to the pharmaceutical and biotech industries.

  9. Therapeutic Expertise: Neuroscience & CNS Datasheet 3/27/2012
    PRA is a leader in the clinical research industry, providing innovative solutions for CNS drug development.
  10. Clinical Trials In Russia 8/26/2011
    The Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (Roszdravnadzor) and the Ministry of Health and Social Development of the Russian Federation (MoH) approved 492 new clinical trials of all types including local and bioequivalence studies during 2010, demonstrating a 15% decrease from the last year figure.